Mitomycin-C as adjuvant therapy in the treatment of sebaceous gland carcinoma in high-risk locations

Authors: Rudkin, Adam K; Muecke, James S

Source: Clinical & Experimental Ophthalmology, Volume 37, Number 4, May/June 2009 , pp. 352-356(5)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Purpose:

To report on the use of Mitomycin-C as adjuvant therapy to excision and cryotherapy in patients with sebaceous gland carcinoma (SGC) in high-risk locations. Design:

Retrospective, consecutive, case series. Participants:

Three patients with SGC of the upper palpebral conjunctiva or caruncle, but without clinical pagetoid spread. Methods:

Following excision and double freeze-thaw cryotherapy, patients with histology demonstrating SGC of the ocular surface were treated with topical Mitomycin-C (0.04%). Follow-up was conducted over an average of 30 months (range: 24-37 months). Main outcome measures:

Postoperative evidence of local recurrence, lymph node or distant organ metastasis. Results:

No patients had evidence of local recurrence or systemic disease. Conclusions:

Wide surgical excision with cryotherapy is the basis of treatment of SGC without pagetoid spread. The use of Mitomycin-C as adjuvant therapy remains controversial, although there is some rationale for its use in high-risk situations.

Keywords: adjuvant; chemotherapy; mitomycin; recurrence; sebaceous gland carcinoma

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1442-9071.2009.02048.x

Affiliations: 1: Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Publication date: 2009-05-01